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Non-technicalsummaryBrainbloodﬂowincreasesduringtheﬁrstweekoflivingathighaltitude.
We do not understand completely what causes the increase or how the factors that regulate brain
blood ﬂow are affected by the high-altitude environment. Our results show that the balance of
oxygen (O2) and carbon dioxide (CO2) pressures in arterial blood explains 40% of the change in
brain blood ﬂow upon arrival at high altitude (5050m). We also show that blood vessels in the
brainrespondtoincreasesanddecreasesinCO2 differentlyathighaltitudecomparedtosealevel,
and that this can affect breathing responses as well. These results help us to better understand
t h er e g u l a t i o no fb r a i nb l o o dﬂ o wa th i g ha l t i t u d ea n da r ea l s or e l e v a n tt od i s e a s e st h a ta r e
accompanied by reductions in the pressure of oxygen in the blood.
Abstract Upon ascent to high altitude, cerebral blood ﬂow (CBF) rises substantially before
returning to sea-level values. The underlying mechanisms for these changes are unclear. We
examined three hypotheses: (1) the balance of arterial blood gases upon arrival at and across
2weeks of living at 5050m will closely relate to changes in CBF; (2) CBF reactivity to steady-state
changes in CO2 will be reduced following this 2week acclimatisation period, and (3) reductions
in CBF reactivity to CO2 will be reﬂected in an augmented ventilatory sensitivity to CO2.W e
measured arterial blood gases, middle cerebral artery blood ﬂow velocity (MCAv, index of
CBF) and ventilation ( ˙ VE) at rest and during steady-state hyperoxic hypercapnia (7% CO2)
and voluntary hyperventilation (hypocapnia) at sea level and then again following 2–4, 7–9 and
12–15days of living at 5050m. Upon arrival at high altitude, resting MCAv was elevated (up
31±31%; P <0.01; vs. sea level), but returned to sea-level values within 7–9days. Elevations
in MCAv were strongly correlated (R2 =0.40) with the change in PaO2/PaCO2 ratio (i.e. the
collective tendency of arterial blood gases to cause CBF vasodilatation or constriction). Upon
initial arrival and after 2weeks at high altitude, cerebrovascular reactivity to hypercapnia
was reduced (P <0.05), whereas hypocapnic reactivity was enhanced (P <0.05 vs. sea level).
Ventilatory response to hypercapnia was elevated at days 2–4 (P <0.05 vs. sea level, 4.01±2.98
vs. 2.09±1.32lmin−1 mmHg−1). These ﬁndings indicate that: (1) the balance of arterial blood
gases accounts for a large part of the observed variability (∼40%) leading to changes in CBF
at high altitude; (2) cerebrovascular reactivity to hypercapnia and hypocapnia is differentially
affected by high-altitude exposure and remains distorted during partial acclimatisation, and (3)
alterations in cerebrovascular reactivity to CO2 may also affect ventilatory sensitivity.
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Introduction
Upon ascent to high altitude, cerebral blood ﬂow (CBF)
rises substantially and then returns towards sea-level
valueswithin1weekofexposureonset(Severinghausetal.
1966b; Huang et al. 1987). The mechanisms underlying
the regulation of CBF during exposure to high altitude
are complex and depend partly on the degree of hypoxic
stimulus itself and on the cerebrovascular sensitivity to
hypoxia and CO2 (Severinghaus, 2001; Ainslie & Ogoh,
2010). The partial pressures of arterial carbon dioxide
(PaCO2)a n do x y g e n( PaO2) play a major role in CBF
regulation. A severe drop in PaO2 (to <40–45mmHg)
produces cerebral vasodilatation (Cohen et al. 1967);
however,whilsthypoxiaperse isacerebralvasodilator,the
hypoxic-induced activation of peripheral chemoreceptor
activity leads to hyperventilatory-induced lowering of
PaCO2 and subsequent cerebral vasoconstriction (Kety &
Schmidt, 1948). The balance between these conﬂicting
changes in arterial blood gases may be expected to alter
during the process of acclimatisation (Severinghaus et al.
1966b; Ainslie & Ogoh, 2010). Surprisingly, a relationship
between changes in CBF and the ‘balance’ or ‘ratio’ of
arterial blood gases upon ascent to high altitude has
not been reported. Upon arrival at high altitude, those
individuals who exhibit a ‘brisk’ ventilatory response
will have a higher PaO2 and lower PaCO2 than those
individuals who have a ‘blunted’ ventilatory response.
Although not established, it would seem reasonable to
anticipate that changes in CBF at high altitude will be
relatedtothebalanceofPaO2/PaCO2 –abalancedetermined
by an individual’s ventilatory sensitivity to the hypoxic
environment (Ainslie & Ogoh, 2010).
In addition to the critical importance of the
prevailing arterial blood gas pressures, another factor
that determines CBF is the relative degree of cerebral
reactivity. Experimental studies that have examined the
inﬂuence of exposure to high altitude (or hypoxia) on
cerebral reactivity are limited and have variable results
(Jansen et al. 1999; Blaber et al. 2003; Ainslie et al. 2007b;
Ainslie&Burgess,2008),andnonehaveinvestigatedwhat
occursduringacclimatisation.Differencesinexperimental
protocol(lengthofhypoxicexposure),methodofassessing
CBF reactivity, degree and type of hypoxic exposure
(simulated vs. high altitude), and limited sample size may
explain the differences in the observed CBF reactivity
following exposure to high altitude. Recently, as assessed
using a modiﬁed rebreathing method, we have reported
that cerebrovascular reactivity and ventilatory sensitivity
are both elevated upon initial (2–4days) arrival at
high altitude (Fan et al. 2010a). Whilst the rebreathing
method clariﬁes some physiological effects associated
with acute exposure to high altitude, it excludes the
natural physiological inﬂuence of ventilatory sensitivity
on cerebrovascular reactivity (Ainslie & Dufﬁn, 2009). An
alternative, integrated approach to explore the inﬂuence
of ventilatory sensitivity on cerebrovascular reactivity is
the use of a steady-state test. The steady-state method
includes the inﬂuence of ventilatory-induced changes in
PCO2 gradients and CBF whereas the rebreathing method
limits this inﬂuence (Fan et al. 2010b).
The implications of alterations in CBF and
cerebrovascular reactivity to CO2 are numerous (for
review see Ainslie & Dufﬁn, 2009), including a potential
impact on ventilatory sensitivity (Xie et al. 2006; Fan
et al. 2010b). For example, reductions in cerebrovascular
CO2 reactivity have been reported in the development of
a heightened ventilatory response to CO2 and unstable
breathing pattern in patients with congestive heart failure
(e.g. Xie et al. 2005) and obstructive sleep apnoea (e.g.
Reichmuth et al. 2009; Burgess et al. 2010). Although
it is acknowledged that peripheral chemoreceptors are
crucial for the development of ventilatory acclimatisation
athighaltitude,changesinCO2sensitivityarealsorelevant
(Dempsey & Forster, 1982) and therefore potentially
inﬂuenced by alterations in cerebrovascular reactivity.
Thethreenewhypothesesofthisstudywerethat:(1)the
balance of arterial blood gases upon arrival at and across
2weeks of living at 5050m will closely relate to changes
in CBF; (2) CBF reactivity to steady-state changes in CO2
will be reduced across a 2week acclimatisation period at
5050m, and (3) the reductions in CBF reactivity to CO2
willbe reﬂectedin an augmentedventilatory sensitivity to
CO2.
Methods
Participants
Seventeenparticipants(11maleand6female;mean± S.D.:
aged 31±9years; height, 1.7±0.1m; body mass,
69±8kg)volunteered forthis study,whichwas approved
by the Lower South Regional Ethics Committee of Otago
and conformed to the standards set by the Declaration of
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Helsinki. Participants were informed of the experimental
procedures and possible risks involved in the study and
written informed consent was obtained. All participants
underwent full medical screening, including ECG and
echo-cardiography assessment. Participants were not
taking any medication, all were non-smokers, and none
had any history of cardiovascular, cerebrovascular or
respiratorydisease. In addition, onlytwo participantshad
previous high-altitude experience, which was >2y ears
previous to this expedition.
Experimental design and ascent protocol
Following full familiarisation with the experimental
procedures (outlined below), the participants underwent
two or four experimental trials: one at sea level (Dunedin,
New Zealand; barometric pressure 755±7 mmHg) and
one or three repeated trials while living at high altitude
(5050m; the Ev-K2-CNR Pyramid Laboratory, Khumbu
Valley, Nepal, at the base of Mt Everest; barometric
pressure 413±1mmHg). The high-altitude trials were
completed upon initial arrival (2–4days) and then a
sub-group of 10 participants were tested twice across a
partial acclimatisation period of ∼2weeks(atda ys7–9
and12–15).Sea-leveltestingwascompleted2weeksbefore
arrivinginNepal.Participantsspent7daysatKathmandu
(∼1400m) before ﬂying to Lukla (2860m). Participants
then trekked to the Ev-K2-CNR Pyramid Laboratory over
an8dayperiod,whichincludedrestdaysatNamcheBazar
(3450m) and Pheriche (4252m).
With the exception of arterial blood gas sampling,
which was conducted following 10min supine rest,
all experiments were performed with participants
in a semi-recumbent position. Each experimental
testing session included an arterial blood gas sample,
instrumentation, a 5min baseline data collection period,
then 4 min of steady-state hyperoxic hypercapnia (7%
CO2–93%O2)and5minofvoluntaryhyperventilationto
induce steady-state hypocapnia. Hyperoxic hypercapnia
was intentionally used in order to eliminate the inﬂuence
of hypoxic-induced peripheral chemoreceptor activation
at high altitude and acutely remove the inﬂuence of hypo-
xia on cerebrovascular tone. For hypocapnia, participants
were instructed and given verbal feedback to increase
ventilation (via depth and frequency) to lower and then
maintain a partial pressure of end-tidal PCO2 (PET,CO2)a t
22±2mmHg(sealevel)and17±2mmHg(5050m).The
order of each respiratory manipulation was randomised
and full recovery was permitted between each trial. These
tests were done between 15:00 and 19:00 at sea level and
12:00 and 19:00 at high altitude. The participants were
instructed to avoid caffeine, alcohol and exercise within
12h prior to the experimental testing.
This study was part of a larger research expedition
and consequently participants took part in a number
of studies conducted during the 2weeks at the Pyramid
Laboratory. However, none of the other studies involved
exercise, and recovery time between testing sessions was
managed to avoid potential confounding results (e.g.
>48hbetweenalldruginterventionstudies).Inaddition,
participants were given low-dose acetazolamide (125mg
bd) for the ﬁrst 7days of ascent as acute mountain
sickness (AMS) prophylaxis, as recommended by others
(Basnyat et al. 2006), to minimise the impact that AMS
has on cerebrovascular and ventilatory responses (Jansen
et al. 1999). Importantly, treatment was discontinued
at day 7 to allow sufﬁcient clearance time (i.e. >48h)
before experimental data were collected, since the
reported half-life for acetazolamide is ∼10h (Ritschel
et al. 1998) and this low-dose quantity is reported
to be 90–100% excreted within 24h of administration
(Richalet et al. 2005). AMS was assessed via the
Lake Louise Questionnaire (LLQ; Roach et al. 1993)
and Environmental Symptoms Questionnaire Cerebral
Symptoms(ESQ-C;Sampsonetal.1983)scoringsystems.
Clinical diagnosis of AMS was determined from a LLQ
score of ≥5 in the presence of a headache and an ESQ-C
score≥0.7,asrecommendedbyothers(Baileyetal.2006).
Measurements of MCAv and arterial blood pressure.
Blood ﬂow velocity in the right middle cerebral artery
(MCAv) was measured using a 2MHz pulsed Doppler
ultrasound system (DWL, Compumedics Ltd, Germany)
using search techniques described elsewhere (Aaslid et al.
1982; Ainslie et al. 2005). The Doppler probe was secured
with a plastic headband device (Spencer Technologies,
USA) to maintain optimal insonation position and angle
throughouttheprotocol.Beat-to-beatmeanarterialblood
pressure (MAP) and heart rate were also monitored
usingﬁngerphotoplethysmography(Finometer,Finapress
MedicalSystems,TheNetherlands)andECG,respectively.
To ensure accurate measurements of MAP, right arm
manual blood pressure measurements by auscultation
werealsomadeperiodicallytocheckandvalidatetheauto-
mated recordings. Fromthese cerebral and blood pressure
data, indices of cerebrovascular resistance (pressure/ﬂow)
and conductance (ﬂow/pressure) were calculated:
CVRi=MAP/MCAvmean and CVCi=MCAvmean/MAP,
respectively.
Measurements and control of respiratory gas exchange.
Participants breathed through a leak-free respiratory
mask (Hans-Rudolph 7900 series, Kansas City, MO,
USA) attached to a Y-shaped two-way non-rebreathing
valve (Hans-Rudolph 7900) or through a mouthpiece
(hyperventilation protocol), while wearing a nose clip.
Inspiratoryﬂowwasmeasuredusingaheatedpneumotach
(Hans-Rudolph 3813) attached to the intake valve of the
maskortothemouthpiece,viaadisposableﬁlter.Pressures
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of end-tidal CO2 (PET,CO2)a n dO 2 (PET,O2) were sampled
from the leak-free mask or from a needle inserted into
the mouthpiece and measured using gas analysers (model
CD-3A, AEI Technologies, Pittsburgh, PA; ML206 and
ML240, ADInstruments). Ventilation (ﬂow, tidal volume,
frequency) and gas values were displayed in real time
during testing (PowerLab, ADInstruments). Prior to each
testing session, the pneumotachograph was calibrated
using a 3-L syringe (Hans-Rudolph 5530) and the gas
analysers were calibrated using known concentrations of
O2 and CO2.
Cardiovascular and cerebrovascular haemodynamics
and respiratory variables were measured continuously
at 200Hz using an analog-to-digital converter
(Powerlab 16/30 ML880, Powerlab 8/30 ML870,
ML240; ADInstruments) interfaced with a computer, and
were subsequently analysed using commercially available
software (Chart v.7, ADInstruments).
Blood gases. Arterial blood variables (pH, partial
pressure of arterial O2 (PaO2), partial pressure of arterial
CO2 (PaCO2), arterial O2 saturation (SaO2), bicarbonate
concentration[HCO3
−],andhaematocrit(Hct))fromthe
radialarterywereobtainedafter10minsupinerestusinga
25-gauge needle into a preheparinised syringe. Following
standardised calibration, all blood samples were analysed
usinganarterialblood-gasanalysingsystem(NPT7series,
Radiometer, Copenhagen, Denmark).
Data analysis
Correction for hypocapnia. To normalise for the cerebral
vasoconstrictive effects of hypocapnia at high altitude on
restingmeasures,absoluteMCAvvalueswerealsoadjusted
for changes in PaCO2 (Bailey et al. 2009):
Adjusted MCAv
=
measured MCAv during high altitude
[1 + (PaCO2 during high altitude − PaCO2 baseline) × 0.03)]
Asusedelsewhere(Baileyetal.2009),thisprocedureallows
for the estimation of the ‘theoretical’ changes in CBF
in the hypoxia environment that would have occurred
in the absence of the hypoxic-induced hyperventilation
and related hypocapnia. In other words, it provides an
estimation of the inﬂuence of hypoxia per se on CBF
without the contrasting inﬂuence of hypocapnia.
Estimation of cerebrovascular reactivity. Cerebro-
vascular reactivity to CO2 w a se x p r e s s e da st h er e l a t i v e
(%) change in MCAv per mmHg change in PET,CO2.
As used in other studies, MCAv and CVRi/CVCi were
expressed as the relative (%) change from baseline
to allow between-study comparisons and to reduce
inter-individual variability that is unrelated to the
experimental manipulation (Xie et al. 2005; Ainslie et al.
2007b).
Hypoxic cerebrovascular reactivity was calculated
to assess the effect of the hypobaric hypoxia on
changes in resting CBF from sea-level values. It was
characterised in three complimentary ways: The relative
change in MCAv divided by: (1) the change in SaO2;
(2) the change in PaCO2;a n d( 3 )t h ec h a n g ei n
PaO2/PaCO2 ratio (i.e.  MCAv/ SaO2,  MCAv/ PaCO2
and  MCAv/( PaO2/PaCO2), respectively). Since the
 MCAv is relatively insensitive to hypoxia (at sea level),
but sensitive to  PCO2, the use of the  MCAv/ PaCO2
index provides a means to assess the MCAv response to
the related hypoxic-induced hypocapnia (Ainslie et al.
2007a).
Statistical analysis
Datawereaveragedovertheﬁnalminuteofbaseline,hypo-
capnia and hypercapnia conditions. The time course of
change for all measures was examined using linear mixed
modelling (SPSS 17.0, SPSS Inc., IL, USA), which can
be employed for unbalanced and mixed (between- and
within-subjects factors) repeated measures designs, such
asinthepresentstudy(Cnaanetal.1997).Mainandinter-
action effects of time (4 levels) and group (2 levels) were
tested,withpair-wisecomparisons(Bonferronicorrected)
to identify differences between test-time. A planned
comparison was also conducted to assess changes from
sea-level measures. For all variables tested there was no
difference between groups nor was there an interaction
effect, therefore all participants were pooled into one
group at sea level and upon initial arrival at high altitude.
All data are expressed as mean± S.D. Statistical inferences
werebasedonanα-levelof0.05.Therelationshipbetween
changes in MCAv and the blood gas balance (i.e. the
PaO2/PaCO2 ratio) at high altitude from sea-level values
was tested using linear regression.
Results
Arterial blood gases, cerebrovascular and
cardiovascular alterations at rest
Participants’ arterial blood gases showed the expected
initial respiratory alkalosis at high altitude, which was
corrected with partial acclimatisation over the 14days
(Table1). As anticipated, the lowest PaO2 and the
highest PaCO2 were observed at days 2–4, although the
subsequentrecoveryinPaO2 wasnotstatisticallysigniﬁcant
or as pronounced as that for SaO2 (Table1). Upon initial
arrivalathighaltitude,MCAvwaselevated(up31±31%,
P <0.01) compared to sea level, but returned to sea-level
values by 7–9days (P =0.30; Table1 and Fig.1). Heart
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Table 1. Arterial blood gases and cardiovascular and cerebrovascular function at sea level and
across the initial 2 weeks following ascent to high altitude (5050 m)
Parameter Sea level High altitude
2–4 days 7–9 days 12–15 days
(n = 17) (n = 17) (n = 10) (n = 10)
Arterial blood gases
PaO2 (mmHg) 105 ± 11 44 ± 3∗ 46 ± 3∗ 48 ± 3∗
PaCO2 (mmHg) 42 ± 32 9 ± 3∗ 28 ± 2∗ 26 ± 2∗†
pH 7.45 ± 0.04 7.47 ± 0.03∗ 7.45 ± 0.02 7.43 ± 0.03†
[HCO3
−] (mmol.L−1)2 8 .6 ± 3.12 1 .3 ± 2.4∗ 19.0 ± 2.3∗ 17.1 ± 2.4∗†
SaO2 (%) 98.4 ± 0.57 9 .9 ± 3.4∗ 82.9 ± 3.2∗ 85.5 ± 1.7∗†
Hct (%) 45.0 ± 3.94 5 .7 ± 3.94 9 .4 ± 4.0∗† 51.0 ± 5.0∗†
PaO2/PaCO2 2.5 ± 0.41 .5 ± 0.2∗ 1.7 ± 0.2∗ 1.9 ± 0.3∗†
Cardiovascular function
HR (beats min−1)7 0 ± 11 80 ± 10∗ 80 ± 10∗ 78 ± 10∗
MAP (mmHg) 81 ± 14 90 ± 15 83 ± 68 2 ± 9
Respiratory
˙ VE (l min−1)1 3 .5 ± 1.81 6 .3 ± 4.2∗ 18.8 ± 4.7∗ 22.4 ± 5.9∗†
Cerebrovascular function
MCAv (cm s−1)6 6 ± 11 85 ± 17∗ 71 ± 10† 69 ± 10†
Systolic MCAv (cm s−1) 112 ± 20 130 ± 22∗ 114 ± 15 109 ± 16†
Diastolic MCAv (cm s−1)4 3 ± 66 3 ± 14∗ 51 ± 9∗† 49 ± 7∗†
1Adjusted MCAv (cm s−1)6 6 ± 11 138 ± 24∗ 118 ± 25∗ 125 ± 27∗
CVR (mmHg cm s−1)1 .26 ± 0.36 1.07 ± 0.23 1.18 ± 0.18 1.24 ± 0.33
CVC (cm s−1 mmHg−1)0 .85 ± 0.24 0.97 ± 0.18 0.86 ± 0.12 0.85 ± 0.18
Values are means ± S.D. PaCO2, arterial PCO2; PaO2, arterial PO2;H C O 3
−, bicarbonate; SaO2,
arterial O2 saturation; Hct, haematocrit concentration; HR, heart rate; MAP, mean arterial
blood pressure; ˙ VE, ventilation; MCAv, middle cerebral artery blood ﬂow velocity; CVR, cerebral
vascular resistance; CVC, cerebral vascular conductance. ∗P < 0.05: difference compared
with sea level; †P < 0.05: difference compared with days 2–4 at high altitude. 1Adjusted
MCAv is measured MCAv during high altitude/[1 + (PaCO2 during high altitude − PaCO2 base-
line) × 0.03)]; this procedure allows for the estimation of the ‘theoretical’ changes in cerebral
blood ﬂow in the hypoxia environment that would have occurred in the absence of the
hypoxic-induced hyperventilation and related hypocapnia.
rate was elevated upon initial arrival at high altitude (up
11±13beats, P <0.01) and remained elevated over the
14days(Table1).Nosigniﬁcantchangesinbloodpressure,
cerebral vascular resistance (CVR) and conductance
(CVC) were observed across the acclimatisation period
compared to sea level (all P >0.05; Table1).
The theoretical inﬂuence of hypoxia per se on MCAv
decreased during the acclimatisation period, as shown by
the CO2-adjusted MCAv data in Table1. This adaptation
over time is consistent with the PaO2/PaCO2 ratio (Table1
andFig.1)andthereducedsensitivitytohypoxia(Table2)
across the partial acclimatisation.
Cerebrovascular and ventilatory reactivities to CO2
Cerebrovascular reactivity to hypercapnia was lower on
a v erageatallthr eetestingtimesathighaltitudec ompar ed
tosealevel(Figs3and4B);however,statisticalsigniﬁcance
was only reached at days2–4 (down 26±43%, P =0.02;
n=17) and at days12–15 (down 24±30%, P =0.03;
n=10). Cerebrovascular reactivity to hypocapnia was
elevatedatdays2–4(up153±80%,P <0.01),aresponse
which persisted during the 2weeks (up 70±47% at
days12–15; Fig.3). CVR for hypercapnia reactivity tests
were greater (1.1 vs. 0.9mmHgcms−1, P =0.03) upon
initialarrivalcomparedtosealevel,andremainedelevated
at days7–9 (1.2mmHgcms−1, P <0.01 vs. sea level)
anddays12–15(1.1mmHgcms−1,P =0.01vs.sealevel).
CVR for the hypocapnia tests was unchanged, P =0.74)
across the 2week period from the sea-level measure
(1.7mmHgcms−1). Ventilatory response to hypercapnia
waselevateduponarrivalathighaltitude(up111±127%,
P =0.01; 2.1±1.3 and 4.0±3.0lmin −1 mmHg−1,s e a
levelanddays2–4,respectively)and,onaverage,remained
elevatedacrossthe2weekslivingathighaltitude,although
not statistically so (P >0.05 vs. sea level; 3.7±1.9
and 3.2±1.5lmin−1 mmHg−1, days 7–9 and 12–15,
respectively; Fig. 4A).
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Discussion
T h em a i nn o v e lﬁ n d i n g so ft h i ss t u d yw e r et h a t :( 1 )
the balance of arterial blood gases, which are essentially
determinedbyventilatorysensitivity,accountedforalarge
part of the observed variability leading to changes in
CBF at high altitude; (2) cerebrovascular reactivity to
hypercapnia and hypocapnia were differentially affected
and remained distorted during partial acclimatisation
to high altitude; and (3) alterations in cerebrovascular
reactivity to CO2 may also affect ventilatory sensitivity.
The following discussion considers the evidence,
methodologicalassumptionsandtherelevanceunderlying
the ﬁndings of this study.
Time course of changes in CBF at high altitude
S i n c eﬁ r s tr e p o r t e db yS e v e r i n g h a u sa n dc o l l e a g u e s
(1966b), the increased CBF upon initial exposure to high
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Figure 1. Cerebral blood ﬂow velocity (MCAv, A) and ratio of
arterial blood gases (PaO2/PaCO2, B) for eucapnic (room air) at
sea level and upon initial arrival (2–4 days, n = 17) and
following 7–9 days and 12–15 days (n = 10) of living at high
altitude (5050 m)
∗P < 0.05: difference compared with sea level; †P < 0.05: difference
compared with days 2–4 at high altitude. The linear mixed model
used revealed no difference between partial and full data sets nor
was there an interaction effect; therefore, all participants were
pooled into one group across the four time points.
altitude and subsequent normalisation after a period of
acclimatisation has been well described (Huang et al.
1987; Wolff, 2000; Ainslie & Ogoh, 2010). Importantly,
the changes that we observed using transcranial Doppler
(up 31%) were similar to those previously reported using
different measuring techniques; e.g. Severinghaus et al.
(1966b), using the Kety–Schmidt method, reported that
CBF increased 24% on arrival (6–12h) at high altitude
(3810m). The mechanisms underlying the regulation
of CBF during exposure to hypoxia are inﬂuenced by
the extent of the hypoxic stimulus itself and on the
cerebrovascular sensitivity to hypoxia and CO2 (Ainslie &
Ogoh, 2010), acting in an interactive way (Severinghaus,
2001). The novel information that the current study
contributes is the time course of the increase and
subsequent normalisation of CBF at high altitude, along
with the alterations in blood gas balance across this time
course. For example, the low PaO2-to-PaCO2 ratio at days
2–4 indicates a greater degree of hypoxic vasodilatation
for a given hypocapnic vasoconstriction (Fig.1) – this
balance, prior to ventilatory acclimatisation, accounts for
∼40% of the initial increase in CBF upon arrival at high
altitude(Fig.2).Ourdataindicatethat,within7–9daysof
livingathighaltitude,normalisationofCBFoccursdueto
hypoxic-induced elevations in ventilation (Table1). This
inﬂuence leads to a higher PaO2-to-PaCO2 ratio, although
only reaching statistical signiﬁcance at days 12–15
(P <0.01vs.days2–4),andthereforelesshypoxic-induced
dilatation and more hypocapnic-induced constriction in
the cerebral circulation. Consistent with these ﬁndings
are the adjusted MCAv data (Table1) and the reduced
hypoxic sensitivity at days7–9 and 12–15 compared to
initial arrival at high altitude (days2–4, Table2). These
analyses reveal that the hypoxic vasodilatory contribution
to CBF, independent of the changes in PaCO2,i sg r e a t e s t
upon initial arrival at high altitude prior to ventilatory
adjustments, and that the theoretical inﬂuence of hypo-
xia per se on MCAv is reduced during acclimatisation.
Importantly, although the ventilatory acclimatisation
relieves some of the hypoxaemia, it is not sufﬁcient to
remove the hypoxic vasodilatory effect altogether, since
thenormalisedMCAvisstillelevatedcomparedtosealevel
(Table1).
Other mechanisms. We have shown for the ﬁrst time that
changes in the balance of arterial blood gases explain
approximately 40% of the variance underlying the initial
elevation in CBF at high altitude. It is acknowledged,
however, that the CBF response upon arrival and during
acclimatisation is affected by a myriad of other factors
(reviewed in Ainslie & Ogoh, 2010). For example, CBF
is increased by factors such as: neuronal (Golanov &
Reis, 1996; Golanov et al. 2001); adenosine (Meno
et al. 1993) and endothelium-derived NO (Faraci &
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Table2. Calculatedhypoxiccerebrovascularreactivity2 toambientconditionsatrestacrosstheinitial2 weeksfollowing
ascent to high altitude (5050 m)
Parameter Sea level High altitude
2–4 days 7–9 days 12–15 days
Hypoxic cerebrovascular reactivity, % MCAv/ SaO2 —1 .7 ± 1.30 .3 ± 0.8† 0.1 ± 1.1†
Hypoxic cerebrovascular reactivity, % MCAv/ PaCO2 —2 .9 ± 2.80 .4 ± 0.9† 0.2 ± 1.0†
Hypoxic cerebrovascular reactivity, % MCAv/ PaO2/PaCO2 —3 1 .1 ± 20.94 .3 ± 13.0† 1.7 ± 19.5†
†P < 0.05: difference compared with days 2–4 at high altitude. 2Hypoxic cerebrovascular reactivity was characterised in
three complimentary ways to assess the effect of the hypobaric hypoxia on changes in resting cerebral blood ﬂow from
sea-level values. These analyses revealed that the hypoxic vasodilatory contribution to cerebral blood ﬂow is greatest
upon initial arrival at high altitude prior to ventilatory adjustments, and that the theoretical inﬂuence of hypoxia per
se on MCAv is reduced during acclimatisation.
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Figure 2. Relation between changes in MCAv and changes in the ratio of arterial blood gases
Relation between per cent changes in MCAv and changes in the ratio of arterial blood gases at sea level and upon
initial arrival (A,2 – 4d a y s ,n = 17), following 7–9 days (B) and 12–15 days (C, n = 10) of living at high altitude
(5050 m). Also presented is the pooled data set (D).
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Brian, 1994; Bailey et al. 2009), whilst CBF is reduced
due to a greater expression of superoxide (Toda et al.
2009) and noradrenaline (Rostrup, 1998), as well as
increased haematocrit (Sorensen et al. 1974). The relative
contributions of these factors in modulating CBF at
high altitude is currently unknown and most probably
change during acclimatisation, as we observed here for
the inﬂuence of the arterial blood gas balance (Fig.2). In
addition, because of the apparent reductions in cerebral
autoregulation at high altitude (Van Osta et al. 2005;
Ainslie et al. 2007b; Jansen et al. 2007), which persist even
following 4weeks of acclimatisation (Iwasaki et al. 2010),
subtlechangesinbloodpressuremayhavehadsomeminor
contribution to the time course changes in the MCAv.
However, the lack of statistical changes we observed in
blood pressure and subsequent relationship to CBF over
this time indicates that its contribution is relatively minor
compared to the balance of arterial blood gases.
Cerebrovascular reactivity
At sea level, steady-state cerebrovascular reactivity is
more sensitive to increases in PCO2 (i.e. hypercapnic
reactivity) than decreases (i.e. hypocapnic reactivity)
(Ide et al. 2003; Xie et al. 2005; Peebles et al. 2007).
Data from the present study indicate that this relation
is reversed upon initial arrival at high altitude, while
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Figure 3. Changes in MCAv from baseline (eucapnia) during a
5 min voluntary hyperventilation (hypocapnia) and a 4 min
steady-state hypercapnia (7% CO2) at sea level and after 2–4,
7–9 and 12–15 days of living at high altitude (5050 m). Group
cerebrovascular reactivity (% MCAv/mmHg CO2; mean ± S.D.)
for each slope (hypercapnia and hypocapnia) at sea level and
during 2 weeks at high altitude.
∗P < 0.05: difference compared with sea level; †P < 0.05: difference
compared with days 2–4 at high altitude. These data indicate that
cerebrovascular reactivity to hypercapnia and hypocapnia is
differentially affected by high-altitude exposure and remains
distorted during partial acclimatisation.
following partial acclimatisation, hyper- and hypocapnia
cerebrovascular reactivity were similar to one another
and both signiﬁcantly different to sea-level responses.
Speciﬁcally, both steady-state hypercapnic and hypo-
capnic reactivity were altered (down 26% and up 153%,
respectively; both P <0.05 vs. sea level) upon arrival at
5050m; responses that remained affected across a 2week
acclimatisation period (at days 12–15; down 24% and up
70%,respectively;bothP <0.05vs.sealevel;Figs3and4).
In addition, Fig.5 shows the typical response across the
2week acclimatisation for one individual, which clearly
shows the reduced hypercapnic reactivity at high altitude
compared to the sea-level response.
Jansen et al. (1999) has proposed that the augmented
hypocapnic and reduced hypercapnic cerebrovascular
reactivity at high altitude could potentially be explained
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Figure 4. Individual ventilatory (A) and middle cerebral artery
blood ﬂow velocity (MCAv; B) responses to hypercapnia
during wakefulness at sea level and after 2–4 days (n = 17), as
well as at 7–9 days and 12–15 days of living at high altitude in
a sub-group (n = 10) of participants
The mean of the group is also presented with an embolden line.
∗P < 0.05; difference compared with sea level. Participant symbols
are consistent between each ﬁgure and statistical signiﬁcance is not
altered with the exclusion of the ‘outlier’ (open square symbol).
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by a resetting of the total cerebral vasomotor reactivity
(the sum of the fractional dilatation during hyper-
capnia and the fractional vasoconstriction during hypo-
capnia).Thealteredhypocapnicreactivityobservedinthe
current study is consistent to that observed by Jansen
et al. (1999), who reported a 71% higher reactivity in
healthy newcomers to high altitude (4243m) compared
to a separate group of sea-level controls. Our data
Figure 5. Representative recordings from one participant at sea level and after 2–4 days and 12–15 days
of living at high altitude (5050 m)
A shows end-tidal PCO2 (PET,CO2, top row) and cerebral blood ﬂow velocity (MCAv, bottom row) during a 4 min
hypercapnic hyperoxia (7% CO2–93% O2) steady-state breathing protocol preceded by 30 s of room-air breathing.
B shows these same data during the ﬁrst 4 min of forced hyperventilation preceded by a 30 s of room-air breathing
baseline. Ventilation (l min−1) at rest for room-air breathing and during the hypercapnia reactivity protocol (A)i s
presented along with the calculated CO2 reactivity (A and B) at each time point. These data illustrate the persistent
reduction in hypercapnic reactivity and enhanced hypocapnic reactivity after 2 weeks of living at high altitude.
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conﬁrm this observation and importantly do so using
a within-subject study design. Furthermore, the greater
augmentation of hypocapnic reactivity and the signiﬁcant
reduction in hypercapnic reactivity observed in the
present study indicates that higher altitudes than pre-
viously examined may alter cerebrovascular reactivity to a
greater extent in healthy newcomers to high altitude. We
had previouslyreported that the MCAv responseto hypo-
capnia (voluntary hyperventilation) was blunted (Ainslie
et al. 2007b) or unchanged (Ainslie & Burgess, 2008) at
3840m, which conﬂicts with our present ﬁndings. One
explanation for these differences is that the participants
in our earlier study were tested following a 9day ascent
to altitudes >5000m. Therefore, perhaps the descent
(i.e. relative deacclimatisation), and related changes in
arterial blood gases, from those at higher altitude are
relevant in opposing the hypocapnia reactivity response.
Recently,ithasbeensuggestedthataugmentedhypocapnic
reactivity at high altitude could be an ‘artefact’ because
of the inﬂuence of hyperventilation on elevating PaO2
and thus reducing the hypoxic dilatory stimulus on the
cerebrovasculature (Moller, 2010). There are two relevant
points to this consideration. First, although PaO2 within
thisrangewillhaveaneffectonCBFdilation,itisunlikely
that these changes would be solely responsible for our
ﬁndings. For example, PaO2 increases over this two-week
timeframe(Table1)duetoventilatoryacclimatisation,yet
the heightened hypocapnic reactivity persists – a report
consistent to that observed at a lower altitude (4243
m; Jansen, 1999). Second, regardless of the mechanism
this augmented hypocapnic sensitivity is the physio-
logical reality in cerebrovascular control: that is, a given
drop in PaCO2 at high altitude results in a greater
drop in CBF. The implications of this maybe important
in the pathophysiology of a range of cerebrovascular
disorders at high altitude (e.g., AMS, CSA, cognitive
impairment).
One potential explanation for the reduced dilatory
capacity may be because of increased muscle sympathetic
nervous activity (MSNA), consistently shown to occur
at high altitude using a variety of direct and indirect
MSNAmeasurementtechniques(Saitoetal.1988;Duplain
et al. 1999; Calbet, 2003; Hansen & Sander, 2003).
However, an elevated MCAv response to hypercapnia
during rebreathing protocols that we (Fan et al. 2010a)
and others (Subudhi et al. 2010) have observed during
hypobaric hypoxia (natural and simulated), along with
the likelihood of an additional elevation in MSNA
during such hypercapnic testing (Claassen et al. 2007),
indicates that the mechanism for a reduced hyper-
capnia response during steady-state hypercapnia is more
probably linked to changes in ventilation sensitivity. Such
ﬁndings are consistent with the view that cerebral SNA
is differentially controlled from MSNA (Ainslie & Tzeng,
2010).
Altered cerebrovascular CO2 reactivity inﬂuences
ventilatory sensitivity
In a parallel study to the present study, we observed
an enhanced hypercapnic reactivity response during a
modiﬁed rebreathing protocol (Fan et al. 2010a), whereas
these steady-state data show an attenuated response. The
criticaldifferencebetweenthesteady-stateandrebreathing
methods for the assessment of hypercapnic cerebral
reactivity is that the rebreathing protocol isolates the
cerebrovascular reactivity response from any change in
ventilatory sensitivity (i.e. as a consequence of living at
high altitude), while the steady-state protocol includes
this ventilatory response to PCO2 (Ainslie & Dufﬁn, 2009).
The inﬂuence of changes in ventilation sensitivity at high
altitude is illustrated in these steady-state cerebrovascular
reactivity data. For example, one participant showed a
negative change in MCAv with increased PCO2 (Fig.4B),
which was accompanied by the greatest increase in
ventilatory sensitivity at the same time points (Fig.4A).
Our ﬁndings of a reduction in cerebrovascular reactivity
to CO2 and reciprocal elevations in ventilatory sensitivity
are broadly consistent with the ﬁndings of Xie et al.
(2006) who, using indomethacin to impair hypercapnic
cerebrovascular reactivity in healthy subjects at sea level,
observedanaugmentedhypercapniaventilatoryresponse.
The ﬁndings of Xie et al. highlighted the important role
of cerebrovascular responsiveness in ventilatory control
in the awake human. Thus, in addition to the powerful
contribution of the peripheral chemoreceptors, the extent
to which changes in cerebrovascular reactivity may also
mediate the development of ventilatory acclimatisation
and related breathing instability during sleep at high
altitude warrants future consideration.
Implications
An enhanced CBF responsiveness to hypocapnia may be a
contributing factor to the commonly, but not universally
(Thomas et al. 2010), observed reductions in orthostatic
tolerance during hypoxic conditions (Blaber et al. 2003).
Importantly, the enhanced hypocapnic cerebrovascular
response would increase an individual’s risk of cerebral
ischaemia during transient reductions in PaCO2 and
potentiallymayleadtoimpairedcognitivefunctionduring
exposure to high altitude (Hornbein et al. 1989) and
facilitate neurological injury (Wilson et al. 2009). The
mechanisms underlying these reactivity responses as well
as resting CBF changes warrant further study.
Tight control of the cerebrovascular CO2 reactivity
provides an important regulatory mechanism to
minimise changes in brain [H+]a tt h el e v e lo ft h e
central chemoreceptor, and thereby stabilise breathing
during ﬂuctuating levels of chemical stimuli (Ainslie &
Dufﬁn, 2009). Consequently, a reduction in CBF hyper-
capnic responsiveness to CO2 and/or an augmentation
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in the hypocapnic range, as observed in the current
study, may account in part for the development of peri-
odic breathing commonly observed in newcomers to high
altitude (Ainslie et al. 2007b). The causative link between
altered cerebrovascular function and the occurrence of
breathinginstabilityathighaltitudeisincompletelyunder-
stood and warrants further investigation.
Methodological considerations
Flow vs. velocity. CBFv has been shown to be a reliable
and valid index of CBF (reviewed in Secher et al.
2008; Ainslie & Dufﬁn, 2009) and our ﬁndings mirror
the reported increases in CBF upon initial exposure to
high altitude as determined by the direct Fick method
(Severinghaus et al. 1966b; Roy et al. 1968; Moller et al.
2002). Moreover, since determinations of cerebrovascular
reactivity are based on stimulus–response principles,
absolute CBF values are not as important as reliable
and repeatable recordings with short (beat-to-beat) time
resolution. For these reasons, transcranial Doppler ultra-
sound is a well-suited technique for ﬁeld-based research.
Potential inﬂuence of AMS on cerebrovascular CO2
reactivity. Mostparticipantsdidreportmildsymptomsof
AMS on days 2–4 at high altitude; however, only 4/17 met
clinicaldeﬁnitionsofAMS,andcorrelationsbetweenAMS
score and changes from sea-level values in either MCAv
or hypercapnic cerebrovascular reactivity were negligible
(R2 <0.01) and weak for hypocapnic cerebrovascular
reactivity(R2 =0.12,P =0.17).Furthermore,signiﬁcance
in our results was not altered with the removal of these
fourparticipantsatthistimepoint;assuch,allparticipant
datawereincluded.Moreover,allparticipantswerefreeof
any AMS symptoms at days12–15, a time point where
the altered reactivity responses persisted; thus, we are
conﬁdent that our observed changes upon arrival at
5050m were not confounded by mild AMS. It should
be noted that the current study intentionally avoided the
peakAMSperiod,whichmayexplainthelackofsigniﬁcant
change in blood pressureand pressure/ﬂowindices. Thus,
our observations of increased CBF upon arrival at high
altitudearelikelytounderestimatewhatoccurswithAMS.
Given the higher prevalence of AMS (and high altitude
cerebral oedema) in the unacclimatised visitor to high
altitude (Hackett & Roach, 2001), further investigation is
warrantedtoclarifytheimpactofAMSoncerebrovascular
responses.
Assessment of cerebrovascular CO2 reactivity. We used a
steady-state open circuit method for measuring MCAv
and ventilatory CO2 responsiveness. Accordingly, we
maintained a PCO2 gradient between the blood and the
brain. This approach closely mimics ‘normal’ physio-
logical conditions, especially during sleep when PaCO2
is transiently increased secondary to hypoventilation or
apnoea. A hyperoxic background was used during the
CO2 response tests to reduce the likely inﬂuence of peri-
pherial chemoreﬂex drive. Although we acknowledge that
hyperoxia alone may induce some mild cerebral vaso-
constriction(Ainslieet al. 2008), this would be unlikelyto
affect our results.
It should also be noted that our ‘steady-state’
determination of CBF and ventilatory CO2 sensitivity was
obtained using only two data points (baseline and 7%
CO2). Nevertheless, the steady-state CBF and ˙ VE CO2
sensitivity observed in the present study were comparable
to that reported by Xie et al. (2006), who used four
steady-state data points (baseline, 2%, 4% and 6% CO2).
In addition, because of a ‘resetting’ of the respiratory
chemoreﬂex to a lower PaCO2 at high altitude (Dempsey
& Forster, 1982), and in view of the linear CBF and ˙ VE
responses to CO2 within this physiological range, we feel
that our ﬁndings based on two data points would not be a
confounding factor.
Finally, it is important to note that the absolute
change in PET,CO2 (and therefore [H+]a tt h ec e n t r a l
chemoreceptors) at high altitude was less than that at
sea level (6–7mmHg vs. 13 mmHg). However, given
the logarithmic relation between PCO2 and pH (i.e.
 pH= logPCO2),anychangeinPCO2 athighaltitudewill
resultinagreaterpHchangecomparedwiththeequivalent
sea-levelPCO2 andthusthelowerPaCO2 athighaltitudemay
overestimate the hypercapnia responses (Severinghaus
et al. 1966a). Nevertheless, for reasons of comparison
with previous studies (which did not correct for this),
together with the fact that corrected responses show a
greater impairment in hypercapnia reactivity during the
steady-state protocol and therefore do not change our
overall ﬁndings, we did not present these corrected data.
Conclusion
The balance of arterial blood gases accounted for a large
part of the observed variability leading to changes in
CBF at high altitude. High altitude exposure alters the
cerebrovascular reactivity to hypercapnia and hypocapnia
differentially and they remained distorted during partial
acclimatisation. These alterations in cerebrovascular
reactivity to CO2 may, in part, also affect ventilatory
sensitivity and breathing stability.
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